BIOGEN INC. Payments to Acquire Debt Securities, Available-for-sale
BIOGEN INC. (BIIB) reported Payments to Acquire Debt Securities, Available-for-sale of $748.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-04-29
- BIOGEN INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $748.80M.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $1.17B.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.26B.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $5.14B, a 49.07% increase from fiscal 2022.
- BIOGEN INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $3.45B, a 9.46% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-03-31 | $748.80M 10-Q · filed 2026-04-29 | $1.92B derived: sum of 2 quarters · filed 2026-04-29 | ||
| 2025-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $1.26B 10-K · filed 2026-02-06 | ||
| 2025-09-30 | $91.00M 10-Q · filed 2025-10-30 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-04-29 | $0.00 derived: sum of 3 quarters · filed 2026-04-29 | $0.00 derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-06 | $0.00 10-K · filed 2026-02-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2026-02-06 | $1.02B derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $1.02B derived: sum of 3 quarters · filed 2026-02-06 | $3.82B derived: sum of 4 quarters · filed 2026-02-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $1.02B derived: sum of 2 quarters · filed 2026-02-06 | $3.82B derived: sum of 3 quarters · filed 2026-02-06 | $5.14B 10-K · filed 2026-02-06 |
| 2023-09-30 | $1.02B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $3.82B derived: sum of 2 quarters · filed 2024-10-30 | $5.14B 10-Q · filed 2024-10-30 | $5.78B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $2.80B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.12B 10-Q · filed 2024-08-01 | $4.76B derived: sum of 3 quarters · filed 2025-02-12 | $5.26B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $1.32B 10-Q · filed 2024-04-24 | $1.96B derived: sum of 2 quarters · filed 2025-02-12 | $2.46B derived: sum of 3 quarters · filed 2025-02-12 | $3.64B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $642.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.14B derived: sum of 2 quarters · filed 2025-02-12 | $2.31B derived: sum of 3 quarters · filed 2025-02-12 | $3.45B 10-K · filed 2025-02-12 |
| 2022-09-30 | $494.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.67B derived: sum of 2 quarters · filed 2023-11-08 | $2.81B 10-Q · filed 2023-11-08 | $4.24B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $1.18B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $2.31B 10-Q · filed 2023-07-25 | $3.75B derived: sum of 3 quarters · filed 2024-02-14 | $4.49B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $1.13B 10-Q · filed 2023-04-25 | $2.57B derived: sum of 2 quarters · filed 2024-02-14 | $3.32B derived: sum of 3 quarters · filed 2024-02-14 | $4.03B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $1.44B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $2.18B derived: sum of 2 quarters · filed 2024-02-14 | $2.90B derived: sum of 3 quarters · filed 2024-02-14 | $3.81B 10-K · filed 2024-02-14 |
| 2021-09-30 | $745.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $1.46B derived: sum of 2 quarters · filed 2022-10-25 | $2.37B 10-Q · filed 2022-10-25 | $4.12B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $713.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $1.63B 10-Q · filed 2022-07-20 | $3.38B derived: sum of 3 quarters · filed 2023-02-15 | $4.27B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $913.30M 10-Q · filed 2022-05-03 | $2.66B derived: sum of 2 quarters · filed 2023-02-15 | $3.56B derived: sum of 3 quarters · filed 2023-02-15 | $5.63B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $1.75B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $2.64B derived: sum of 2 quarters · filed 2023-02-15 | $4.71B derived: sum of 3 quarters · filed 2023-02-15 | $6.40B 10-K · filed 2023-02-15 |
| 2020-09-30 | $895.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $2.96B derived: sum of 2 quarters · filed 2021-10-20 | $4.65B 10-Q · filed 2021-10-20 | $5.85B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $2.07B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $3.75B 10-Q · filed 2021-07-22 | $4.95B derived: sum of 3 quarters · filed 2022-02-03 | $6.93B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $1.68B 10-Q · filed 2021-04-22 | $2.89B derived: sum of 2 quarters · filed 2022-02-03 | $4.86B derived: sum of 3 quarters · filed 2022-02-03 | $6.11B derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $1.20B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $3.18B derived: sum of 2 quarters · filed 2022-02-03 | $4.43B derived: sum of 3 quarters · filed 2022-02-03 | $5.25B 10-K · filed 2022-02-03 |
| 2019-09-30 | $1.98B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $3.23B derived: sum of 2 quarters · filed 2020-10-21 | $4.05B 10-Q · filed 2020-10-21 | $5.65B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | $1.25B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $2.08B 10-Q · filed 2020-07-22 | $3.68B derived: sum of 3 quarters · filed 2021-02-03 | $5.00B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $825.00M 10-Q · filed 2020-04-23 | $2.43B derived: sum of 2 quarters · filed 2021-02-03 | $3.75B derived: sum of 3 quarters · filed 2021-02-03 | $6.60B derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $1.60B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $2.92B derived: sum of 2 quarters · filed 2021-02-03 | $5.78B derived: sum of 3 quarters · filed 2021-02-03 | $7.69B 10-K · filed 2021-02-03 |
| 2018-09-30 | $1.32B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $4.17B derived: sum of 2 quarters · filed 2019-10-22 | $6.09B 10-Q · filed 2019-10-22 | |
| 2018-06-30 | $2.86B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $4.77B 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | $1.92B 10-Q · filed 2019-04-24 | |||
| 2017-09-30 | $1.56B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $4.09B 10-Q · filed 2018-10-23 | ||
| 2017-06-30 | $2.54B 10-Q · filed 2018-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |